ChinaBio® Today is the most widely-read source for China life science news and analysis. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China life science companies and industry events, as well as global issues affecting the China life science industry.
Shineco, a China herbal medicine company, announced plans to acquire a 51% stake in Taiwan 's Mayah Biological Holdings. Mayah describes itself as a biotech that focuses on novel chemical and...
Beijing Sinovac's inactivated COVID-19 (Vero Cell) vaccine has started a rolling review in Europe . CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining...
Beijing 's Jacobio Pharma announced US approval to start trials of its KRAS G12C inhibitor in patients with advanced solid tumors. The company plans to enroll patients with non-small cell lung cancer...
Galmed Pharma, an Israeli biopharma, was approved to add a China arm to its global Phase III trial of Aramchol in patients with NASH and fibrosis. Aramchol is a novel fatty acid bile acid conjugate...
Week in Review: CANbridge Licenses LogicBio's Adeno-Associated Virus for Gene Therapies in $591 Million Deal
May 01, 2021
Deals and Financings Beijing 's CANbridge Pharma in-licensed LogicBio’s adeno-associated virus to use with gene therapy candidates for rare diseases in a $581 million deal; In a second agreement,...
CANbridge Pharma of Beijing has acquired Greater China rights to develop maralixibat, a treatment for a set of rare inherited childhood liver diseases caused by impaired bile flow. Mirum Pharma is...
Nanjing Legend Files for EU Approval of BCMA CAR-T
April 30, 2021
Nanjing Legend Biotech filed for EU approval of its BCMA CAR-T candidate in patients with multiple myeloma. In 2017, Legend stunned participants at the US ASCO meeting with the 94% complete remission...
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus (AAV) sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge also will have an...
Shangha'si I-Mab reported positive topline data from a Phase II trial of a selective IL-6 inhibitor in patients with ulcerative colitis. I-Mab says olamkicept is the only clinical stage IL-6 inhibitor...
Week in Review: Zai Lab Raises $750 Million in Private Placement for In-Licensed/Novel Drugs
April 24, 2021
Deals and Financings Shanghai Zai Lab raised an impressive $750 million in a private placement of its dual US/Hong Kong stock for its in-licensing and novel drug development operations; Beijing's...
Junshi Bio Says PD-1 Meets Endpoints in Esophageal Cancer
April 23, 2021
Zai Lab Raises $750 Million in Private Placement
April 21, 2021